Abstract
Malignant pheochromocytoma and paraganglioma (MPP) is a very rare cancer (annual incidence < 1 per million). Here, we report the first academic randomized double-blind phase II study results assessing Sunitinib efficacy compared to placebo.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have